Groprinosin

Groprinosin is an oral medication containing the active ingredient inosine pranobex. It is supplied in tablet form (strength not specified) and is marketed in the European Union as a prescription immunomodulator. The drug belongs to the antiviral and immunostimulant therapeutic classes and works by enhancing cellular immunity. Its mechanism involves modulation of T‑lymphocyte and natural killer cell activity, leading to increased interferon production in the host.

Groprinosin is indicated for viral infections where immune support is beneficial.

- Herpes simplex virus infections (e.g., oral or genital lesions). - Human papillomavirus (HPV) infections, including warts. - Influenza and other acute respiratory viral infections. - Chronic viral infections requiring immunostimulation, such as certain cases of cytomegalovirus. - As an adjunct therapy in immunocompromised patients with viral disease.

The safety profile of Groprinosin includes both frequent mild reactions and rare serious events.

Common: - Nausea or stomach discomfort. - Headache. - Mild fever. - Skin rash or itching. - Elevated liver enzymes (asymptomatic).

Serious: - Severe allergic reaction (anaphylaxis). - Significant liver dysfunction. - Hematologic abnormalities such as neutropenia. - Autoimmune flare‑ups.

Before prescribing Groprinosin, clinicians should evaluate several safety considerations.

- Assess liver function; the drug may affect hepatic enzymes. - Use caution in patients with known hypersensitivity to inosine pranobex. - Monitor blood counts during prolonged therapy. - Consider potential effects on autoimmune conditions. - Evaluate renal function in patients with severe kidney impairment. - Discuss pregnancy and breastfeeding status, as safety data are limited.

Groprinosin may interact with other medicines, requiring attention to avoid adverse outcomes.

Avoid: - Concurrent use with immunosuppressive agents (e.g., high‑dose corticosteroids) that could counteract its immunostimulant effect. - Combination with other antiviral drugs that share metabolic pathways, potentially increasing toxicity.

Use with caution: - Anticoagulants (e.g., warfarin) due to possible alteration of coagulation parameters. - Hepatotoxic medications (e.g., acetaminophen at high doses) because of additive liver stress. - Live vaccines, as enhanced immune response may affect vaccine efficacy. - Drugs that prolong QT interval, given rare cardiac effects.